drugset / Trial / NCT00482430
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
Timeline
- Start
- 2007-09
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK0557 | Small molecule | 10 mg | — |